Clinical Scorecard: Circulating Biomarker Profiles Associated with Skin, Lung, and Gastrointestinal Involvement in Systemic Sclerosis

At a Glance

Key Highlights

• A skin–lung–gut burden framework identified clinically distinct organ co-involvement groups in systemic sclerosis.
• Higher burden groups showed non-random biomarker patterning across immune, inflammatory, and nutritional domains.
• In adjusted models, Anti-Scl-70 positivity and lower albumin showed associations with higher burden groups.
• Unsupervised clustering revealed biomarker-defined subgroups, supporting structured heterogeneity beyond organ counting.

Guideline-Based Recommendations

Diagnosis

• Utilize the 2013 ACR/EULAR classification criteria for systemic sclerosis.

Management

• Consider biomarker profiles, particularly Anti-Scl-70 and albumin levels, in assessing organ involvement.

Monitoring & Follow-up

• Monitor changes in circulating biomarkers as potential indicators of disease progression.

Risks

• Higher organ involvement burden may correlate with increased risk of complications.

Patient & Prescribing Data

314 patients with systemic sclerosis

Biomarker patterns may inform monitoring strategies.

Clinical Best Practices

• Integrate biomarker analysis with clinical assessments to evaluate organ involvement.

Related Resources & Content

• Systemic Sclerosis Overview